Skip to main content
. Author manuscript; available in PMC: 2020 Feb 1.
Published in final edited form as: Pharmacol Res. 2018 Jul 17;140:75–84. doi: 10.1016/j.phrs.2018.07.018

Figure 2.

Figure 2.

Deficits in trabecular bone of DSS-inflamed mice were protected in mice with attenuated 5-HT synthesis. A. Trabecular thickness and spacing in DSS-inflamed mice receiving PCPA (300mg/kg/day IP, daily) were similar to those observed in control mice, showing a protective effect of this treatment on bone mass. Bone volume fraction, bone surface and connective density were also significantly increased in the PCPA-treated DSS mice compared to DSS mice, but did not reach the levels measured in control mice. B. Representative images from μCT scans of the femoral trabecular bone from two mice per group. Vehicle/Vehicle, n=10; Vehicle/DSS, n=7; PCPA/DSS, n=14. * P < 0.05, *** P < 0.001, ****P < 0.0001; 1-way ANOVA with Bonferroni’s correction.